Information Provided By:
Fly News Breaks for January 10, 2020
CRL
Jan 10, 2020 | 06:24 EDT
Goldman Sachs analyst Robert Jones upgraded Charles River to Buy from Neutral with a price target of $179, up from $143. The analyst considers the outsourced R&D industry's trajectory to be intact into 2020 across preclinical and clinical phases of drug development. 2020 is set to be a strong biologics/small molecule launch year, which is a tailwind to Charles River's MS segment, Jones tells investors in a research note. He expects more consistency in results and sees an attractive entry point at current share levels.
News For CRL From the Last 2 Days
There are no results for your query CRL